Featured Research

from universities, journals, and other organizations

Targeted Cancer Therapy May Treat Resistant Gynecologic Cancers

Date:
March 25, 2014
Source:
Society of Gynecologic Oncology
Summary:
Veliparib, an oral cancer drug, improves outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies, suggests preliminary research.

An oral cancer drug improves outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies, suggests preliminary research. Gynecologic cancer cells that have a BRCA mutation appear to be sensitive to veliparib, which targets an enzyme called PARP (poly ADP-ribose polymerase), according to a Phase II study being presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in Tampa, Fla., March 22-25.

Related Articles


PARP inhibitors prevent cancer cells from repairing themselves after experiencing DNA damage (for example from chemotherapy or radiation). Research has previously shown that veliparib is effective in combination with chemotherapy, but little data was available to indicate whether veliparib was effective as a single agent. Results of this multicenter trial suggest that it is.

“One criticism of the PARP drugs is they are not active in patients who have developed resistance to other therapies, but we found veliparib appears to be effective in some platinum-resistant patients with recurrent or persistent disease,” said Robert L. Coleman, MD, lead author of the study and professor and vice chair of clinical research at the University of Texas MD Anderson Cancer Center, Houston. “Most of these patients have run out of treatment options, and it is very hopeful to potentially have another therapy to offer them.”

In the study, 50 patients with BRCA gene mutations treated at one of 18 centers took veliparib by mouth twice a day. The median number of monthly treatment cycles was six (ranging from one to 22). Overall, 13 patients (26 percent) responded positively to the therapy, meaning the tumors shrank in size, including two patients in whom the tumors disappeared completely. In addition, disease was stabilized for more than four months in nearly half of the women (24).

“Patient recruitment can be a problem for many clinical trials, however, this one filled up very quickly, which reflects that women and their doctors understand that PARP inhibitors hold real promise,” said Dr. Coleman.


Story Source:

The above story is based on materials provided by Society of Gynecologic Oncology. Note: Materials may be edited for content and length.


Cite This Page:

Society of Gynecologic Oncology. "Targeted Cancer Therapy May Treat Resistant Gynecologic Cancers." ScienceDaily. ScienceDaily, 25 March 2014. <www.sciencedaily.com/releases/2014/03/140325094221.htm>.
Society of Gynecologic Oncology. (2014, March 25). Targeted Cancer Therapy May Treat Resistant Gynecologic Cancers. ScienceDaily. Retrieved November 24, 2014 from www.sciencedaily.com/releases/2014/03/140325094221.htm
Society of Gynecologic Oncology. "Targeted Cancer Therapy May Treat Resistant Gynecologic Cancers." ScienceDaily. www.sciencedaily.com/releases/2014/03/140325094221.htm (accessed November 24, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, November 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Winter Can Cause Depression — Here's How To Combat It

Winter Can Cause Depression — Here's How To Combat It

Newsy (Nov. 23, 2014) Millions of American suffer from seasonal depression every year. It can lead to adverse health effects, but there are ways to ease symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com
WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins